Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with Myelodysplastic Syndromes
Background Myelodysplastic Syndromes (MDS) are a group of heterogeneous diseases originating from bone marrow hematopoietic stem cells, characterized by reduced blood cell production. Although certain progress in treatment has been made in recent years, allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only potentially curative ...